vTv Therapeutics Inc. (VTVT)
16.54
0.14 (0.85%)
At close: Apr 02, 2025, 2:41 PM
17.18
3.85%
After-hours: Apr 02, 2025, 07:55 PM EDT
0.85% (1D)
| Bid | 15.09 |
| Market Cap | 43.21M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -3.2 |
| PE Ratio (ttm) | -5.17 |
| Forward PE | -2.98 |
| Analyst | Buy |
| Ask | 19.85 |
| Volume | 1,688 |
| Avg. Volume (20D) | 22,328 |
| Open | 16.54 |
| Previous Close | 16.40 |
| Day's Range | 16.54 - 16.54 |
| 52-Week Range | 12.12 - 29.19 |
| Beta | 1.07 |
About VTVT
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is a...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2015
Employees 23
Stock Exchange NASDAQ
Ticker Symbol VTVT
Website https://www.vtvtherapeutics.com
Analyst Forecast
According to 1 analyst ratings, the average rating for VTVT stock is "Buy." The 12-month stock price forecast is $35, which is an increase of 111.61% from the latest price.
Stock Forecasts2 weeks ago
+53.13%
vTv Therapeutics shares are trading higher after t...
Unlock content with
Pro Subscription
8 months ago
-24.53%
vTv Therapeutics shares are trading lower after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program.
